Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Meningioma and schwannoma management, and MRI in cancer diagnosis.
Management of brain tumour related epilepsy (BTRE): a narrative review and therapy recommendations.
CTNI-14. RADIOTHERAPY VERSUS TMZ FOR HIGH-RISK LOW-GRADE GLIOMA. FINAL RESULTS AFTER MEDIAN FOLLOW-UP OF 13 YEARS OF PHASE III EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) STUDY
Radiation and the nervous system.
Eligibility to drive and neurology: the how and the why.
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma.
Longitudinal structural and perfusion MRI enhanced by machine learning outperforms standalone modalities and radiological expertise in high-grade glioma surveillance.
A case study investigating the role of the anterior temporal lobes in general semantics and semantics specific to persons, emotions and social conceptual knowledge.
Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.
Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know.
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes.
Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better.
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma.
Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033).